These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28427007)

  • 1. Novel and revisited approaches in antituberculosis drug discovery.
    Herrmann J; Rybniker J; Müller R
    Curr Opin Biotechnol; 2017 Dec; 48():94-101. PubMed ID: 28427007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents.
    Farah SI; Abdelrahman AA; North EJ; Chauhan H
    Assay Drug Dev Technol; 2016; 14(1):29-38. PubMed ID: 26565779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents.
    Cooper CB
    J Med Chem; 2013 Oct; 56(20):7755-60. PubMed ID: 23927683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target discovery focused approaches to overcome bottlenecks in the exploitation of antimycobacterial natural products.
    Baptista R; Bhowmick S; Nash RJ; Baillie L; Mur LA
    Future Med Chem; 2018 Apr; 10(7):811-822. PubMed ID: 29569936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH; Smith PW
    Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current challenges in drug discovery for tuberculosis.
    Kumar A; Chettiar S; Parish T
    Expert Opin Drug Discov; 2017 Jan; 12(1):1-4. PubMed ID: 27797593
    [No Abstract]   [Full Text] [Related]  

  • 8. Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discovery.
    Cazzaniga G; Mori M; Chiarelli LR; Gelain A; Meneghetti F; Villa S
    Eur J Med Chem; 2021 Nov; 224():113732. PubMed ID: 34399099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the tuberculosis drug development pipeline.
    Evangelopoulos D; McHugh TD
    Chem Biol Drug Des; 2015 Nov; 86(5):951-60. PubMed ID: 25772393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in natural product-based drug discovery for tuberculosis.
    Dong M; Pfeiffer B; Altmann KH
    Drug Discov Today; 2017 Mar; 22(3):585-591. PubMed ID: 27890820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery.
    Ekins S; Freundlich JS; Hobrath JV; Lucile White E; Reynolds RC
    Pharm Res; 2014 Feb; 31(2):414-35. PubMed ID: 24132686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives on natural products in TB drug research.
    Pauli GF; Case RJ; Inui T; Wang Y; Cho S; Fischer NH; Franzblau SG
    Life Sci; 2005 Dec; 78(5):485-94. PubMed ID: 16243360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on tuberculosis pathogenesis and discovery of anti- tubercular drugs.
    Ntie-Kang F; Yong JN; Owono Owono LC; Sippl W; Megnassan E
    Curr Med Chem; 2014; 21(30):3466-77. PubMed ID: 25005178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereochemistry at the forefront in the design and discovery of novel anti-tuberculosis agents.
    Huang Q; He R; Kozikowski AP
    Curr Top Med Chem; 2011; 11(7):810-8. PubMed ID: 21291395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tuberculosis drug discovery and development pipeline and emerging drug targets.
    Mdluli K; Kaneko T; Upton A
    Cold Spring Harb Perspect Med; 2015 Jan; 5(6):. PubMed ID: 25635061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current perspectives in drug discovery against tuberculosis from natural products.
    Nguta JM; Appiah-Opong R; Nyarko AK; Yeboah-Manu D; Addo PG
    Int J Mycobacteriol; 2015 Sep; 4(3):165-83. PubMed ID: 27649863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enabling faster Go/No-Go decisions through secondary screens in anti-mycobacterial drug discovery.
    Mukherjee R; Chandra Pal A; Banerjee M
    Tuberculosis (Edinb); 2017 Sep; 106():44-52. PubMed ID: 28802404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
    Kigondu EM; Wasuna A; Warner DF; Chibale K
    Bioorg Med Chem; 2014 Aug; 22(16):4453-61. PubMed ID: 24997576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host-pathogen systems for early drug discovery against tuberculosis.
    Trofimov V; Costa-Gouveia J; Hoffmann E; Brodin P
    Curr Opin Microbiol; 2017 Oct; 39():143-151. PubMed ID: 29179041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.